COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #19 of 237
4/26 Late treatment study
Auld et al., Critical Care Medicine, doi:10.1097/ccm.0000000000004457 (Peer Reviewed)
ICU and ventilator mortality among critically ill adults with COVID-19
Source   PDF   Share   Tweet
Retrospective 217 critically ill patients, 114 receiving HCQ, showing no significant difference in mortality.

Auld et al., 4/26/2020, retrospective, USA, North America, peer-reviewed, 14 authors.
risk of death, 2.8% higher, RR 1.03, p = 1.00, treatment 33 of 114 (28.9%), control 29 of 103 (28.2%).
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit